AIRS · Airsculpt Technologies, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $8.25M | first six months of 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 10% | first six months of 2026 | — |
| Adjusted net (loss)/income non-GAAP | -$211K | Six Months Ended June 30, 2026 | — |
| Adjusted net loss per share of common stock non-GAAP | $0 | Six Months Ended June 30, 2026 | — |
| Case growth | -0.5% | Three Months Ended June 30, 2026 filing | — |
| Case volume | 6,458 | first six months of 2026 | — |
|
|
|||
| Cases | 6,458 | Six Months Ended June 30, 2026 | — |
| Customer acquisition costs per customer | $3,467 | the three months ended June 30, 2026 filing | — |
| Number of facilities | 31 | Six Months Ended June 30, 2026 | — |
| Number of total procedure rooms | 65 | Six Months Ended June 30, 2026 | — |
| Revenue per case | $12,742 | Six Months Ended June 30, 2026 | — |
| Revenue per case growth | -2.1% | Three Months Ended June 30, 2026 filing | — |
| Same-center case growth | 1.1% | first six months of 2026 (YTD) | — |
| Same-center Cases | 6,458 | Six Months Ended June 30, 2026 | — |
| Same-center Revenue per case | $12,742 | Six Months Ended June 30, 2026 | — |
| Same-center revenue per case growth | -2% | Q2 2026 | — |
| Same center sales | 1% | first quarter of 2026 | — |
| same-store revenue | -16% | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AIRS
this stock
Airsculpt Technologies, Inc.
|
$247.29M | +73.2% | -15.8% | — | 3.8% |
|
HCA
HCA Healthcare, Inc.
|
$89.77B | -13.3% | +7.1% | 13.9 | 2.7% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.87B | -4.4% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.57B | +34.8% | +0.9% | 10.3 | 4.0% |
|
FMS
Fresenius Medical Care AG
|
$12.65B | -0.2% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AIRS | -31.5% | -22.9% | +107.9% | -28.7% | +73.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -31.9% | -27.4% | +94.1% | -32.6% | +59.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.